Hypophosphatasia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Hypophosphatasia (HPP) is the inborn
error of metabolism caused by a loss-of-function mutation(s) in the gene that
encodes the tissue-nonspecific isozyme of alkaline phosphatase (TNAP). The
disease has been classified according to patient age when the first signs and
symptoms manifest, i.e., perinatal, infantile, childhood, adult HPP. Other
types include odonto HPP and perinatal benign. Babies with the
perinatal/immature forms of HPP often die with severe rickets and respiratory
insufficiency and sometimes hypercalcemia and vitamin B6-responsive seizures.
The primary biochemical defect in HPP is a deficiency of TNAP activity that
leads to elevated circulating levels of substrates, in particular inorganic
pyrophosphate (PPi), a potent calcification inhibitor. The clinical severity of
HPP varies greatly. The disease can be classified according to patient age when
the first signs and symptoms manifest: perinatal, infantile, childhood, and
adult HPP. Additional clinical forms include odonto-HPP, where there are only
dental manifestations, and prenatal benign-HPP.
·
The incidence of Hypophosphatasia (HPP) is a
rare, heritable form with an incidence of 1 in 100,000 population.
Thelansis’s “Hypophosphatasia Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Hypophosphatasia
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Hypophosphatasia across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Hypophosphatasia Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment